BioMarin Pharmaceutical Inc.
BMRN
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPSā¦ read more
Healthcare
Biotechnology
26 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$52.15
Price-2.05%
-$1.09
1Y
Price
Market Cap
$10.080b
Large
Price/Earnings 3y Avg5y Avg
37.5x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+22.5%
EBITDA Margin+13.8%
Net Profit Margin+26.1%
Free Cash Flow Margin+22.5%
EBITDA Margin+13.8%
Net Profit Margin+26.1%
Free Cash Flow MarginRevenue
$3.242b
+0.7%
1y CAGR+10.5%
3y CAGR+11.7%
5y CAGREarnings
$268.742m
-23.0%
1y CAGR+37.8%
3y CAGR+33.0%
5y CAGREPS
$1.39
-22.8%
1y CAGR+36.6%
3y CAGR+31.8%
5y CAGRBook Value
$6.212b
$8.591b
Assets$2.379b
Liabilities$1.440b
DebtDebt to Assets
16.8%
3x
Debt to EBITDAFree Cash Flow
$767.058m
+5.8%
1y CAGR+239.4%
3y CAGR+183.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company